ILARIS (canakinumab/PF)
ANTI-INFLAMMATORY - INTERLEUKIN 1 RECEPTOR ANTAGONIST · ACUTE GOUTY ARTHRITIS ·+7
Novartis Pharmaceuticals
Drug class
Anti-Inflammatory - Interleukin 1 Receptor Antagonist
The therapeutic class "Anti-Inflammatory - Interleukin 1 Receptor Antagonist" comprises biologic agents—most notably recombinant human interleukin-1 receptor antagonists such as anakinra—that selectively inhibit interleukin-1 (IL-1) signaling. Read more about Anti-Inflammatory - Interleukin 1 Receptor Antagonist
4 drugs in this class 3 manufacturers
Drugs in Anti-Inflammatory - Interleukin 1 Receptor Antagonist
ARCALYST (rilonacept)
ANTI-INFLAMMATORY - INTERLEUKIN 1 RECEPTOR ANTAGONIST · MUCKLE-WELLS SYNDROME ·+3
KINIKSA PHARMAC
ILARIS (PF) (canakinumab/PF)
ANTI-INFLAMMATORY - INTERLEUKIN 1 RECEPTOR ANTAGONIST · ACUTE GOUTY ARTHRITIS ·+7
Novartis Pharmaceuticals
ILARIS (canakinumab/PF)
ANTI-INFLAMMATORY - INTERLEUKIN 1 RECEPTOR ANTAGONIST · ACUTE GOUTY ARTHRITIS ·+7
Novartis Pharmaceuticals
Filter & compare in the drug finder →
Opens the drug finder with Anti-Inflammatory - Interleukin 1 Receptor Antagonist preselected. Add indication or manufacturer filters there.
The therapeutic class "Anti-Inflammatory - Interleukin 1 Receptor Antagonist" comprises biologic agents—most notably recombinant human interleukin-1 receptor antagonists such as anakinra—that selectively inhibit interleukin-1 (IL-1) signaling.
These agents exert their anti-inflammatory effects by competitively binding to the cell-surface interleukin-1 type I receptor (IL-1RI), thereby blocking the downstream proinflammatory cascades triggered by both IL-1a and IL-1ß.
Clinically, this drug class is utilized primarily to manage severe autoinflammatory and rheumatic conditions, including rheumatoid arthritis, cryopyrin-associated periodic syndromes, systemic juvenile idiopathic arthritis, and deficiency of the interleukin-1 receptor antagonist.
-
nih.gov
The therapeutic class "Anti-Inflammatory - Interleukin 1 Receptor Antagonist" comprises biologic agents—most notably recombinant human interleukin-1 receptor antagonists such as anakinra—that selectively inhibit interleukin-1 (IL-1) signaling These agents exert their anti-inflammatory effects by competitively binding to the cell-surface interleukin-1 type I receptor (IL-1RI), thereby blocking the downstream proinflammatory cascades triggered by both IL-1α and IL-1β Clinically, this drug class is...
-
nih.gov
The therapeutic class "Anti-Inflammatory - Interleukin 1 Receptor Antagonist" comprises biologic agents—most notably recombinant human interleukin-1 receptor antagonists such as anakinra—that selectively inhibit interleukin-1 (IL-1) signaling
-
wikipedia.org
The therapeutic class "Anti-Inflammatory - Interleukin 1 Receptor Antagonist" comprises biologic agents—most notably recombinant human interleukin-1 receptor antagonists such as anakinra—that selectively inhibit interleukin-1 (IL-1) signaling Clinically, this drug class is utilized primarily to manage severe autoinflammatory and rheumatic conditions, including rheumatoid arthritis, cryopyrin-associated periodic syndromes, systemic juvenile idiopathic arthritis, and deficiency of the interleukin-...
-
trialfriend.com
Clinically, this drug class is utilized primarily to manage severe autoinflammatory and rheumatic conditions, including rheumatoid arthritis, cryopyrin-associated periodic syndromes, systemic juvenile idiopathic arthritis, and deficiency of the interleukin-1 receptor antagonist
Sign in to follow this class
Following a drug class requires a free Physicians Office Resource account.